Description
Stem cells hold great promise in the evolving field of regenerative medicine, and there are many sources from which they can be obtained. Over the past decade different perinatal (Pn) tissues have been shown to harbor a vast array of stem cells with therapeutic potential. This relatively new field of research is rapidly expanding, and its relevance is supported by the recent emergence of clinical trials in Europe and worldwide.
There are, however, many issues that need to be addressed to ensure optimal research outcome and clinical experimentation data interpretation. These issues range from the need to arrive to a consensus on nomenclature and optimal techniques for isolation, characterization, and cryopreservation, to more advanced issues such as collating data and expertise towards an understanding and exploitation of the mechanisms and therapeutic actions of perinatal derivatives. There is also the necessity to identify gaps in knowledge and how collaborative research can address them.
Therefore, this COST Action will unite a currently fragmented a critical mass of academic, clinical, and industry expertise to enhance both basic understanding and translational potential of perinatal derivatives.
The Action will develop a platform for the exchange of concepts, methods, and training of young researchers.
Action keywords
regenerative medicine - translational medicine - stem cells - human term placenta-derived cells - immunomodulation
Management Committee
Country | MC Member |
---|---|
Albania | |
Austria | |
Austria | |
Belgium | |
Belgium | |
Bosnia and Herzegovina | |
Bulgaria | |
Croatia | |
Croatia | |
Czech Republic | |
Estonia | |
Finland | |
Finland | |
France | |
France | |
Germany | |
Germany | |
Greece | |
Greece | |
Ireland | |
Israel | |
Italy | |
Italy | |
Latvia | |
Lithuania | |
Lithuania | |
Luxembourg | |
Malta | |
Malta | |
Norway | |
Poland | |
Portugal | |
Portugal | |
Romania | |
Romania | |
Serbia | |
Slovenia | |
Spain | |
Spain | |
Sweden | |
Sweden | |
Switzerland | |
Switzerland | |
Türkiye | |
United Kingdom | |
United Kingdom |
Main Contacts
Action Contacts
COST Staff
Leadership
Role | Leader |
---|---|
Action Chair | |
Action Vice-Chair | |
Grant Holder Scientific Representative | |
Science Communication Coordinator | |
Grant Awarding Coordinator | |
WG1 Leader | |
WG2 Leader | |
WG3 Leader | |
WG4 Leader | |
WG5 Leader |
Additional roles
Role | Leader |
---|---|
ITC CG Coordinator | |
STSM Coordinator |
Working Groups
Number | Title | Leader |
---|---|---|
1 | IN VITRO CHARACTERIZATION AND CONSENSUS | |
2 | PRECLINICAL STUDIES AND MODELS | |
3 | CLINICAL APPLICATIONS | |
4 | REGULATORY AND ETHICAL ASPECTS | |
5 | DISSEMINATION AND EXPLOITATION |
Membership
Name | Working Group | Country |
---|---|---|
WG 1 | Austria | |
WG 1 | ||
WG 1 | Italy | |
WG 1 | Austria | |
WG 1 | Bulgaria | |
WG 1, WG 4 | Croatia | |
WG 1 | Germany | |
WG 1 | Ireland | |
WG 1 | Italy | |
WG 1 | Lithuania | |
WG 1 | Poland | |
WG 1 | ||
WG 1 | Romania | |
WG 1 | Slovenia | |
WG 1 | Spain | |
WG 1 | Austria | |
WG 1 | ||
WG 1 | ||
WG 1 | ||
WG 1 | Italy | |
WG 1 | ||
WG 1 | ||
WG 1 | Italy | |
WG 1 | Slovenia | |
WG 1 | Italy | |
WG 1 | Slovenia | |
WG 1, WG 2 | Germany | |
WG 1, WG 2, WG 3 | ||
WG 1 | Italy | |
WG 1, WG 5 | Portugal | |
WG 1 | ||
WG 2 | Italy | |
WG 2 | Latvia | |
WG 2 | Belgium | |
WG 2 | France | |
WG 2 | Greece | |
WG 2 | Greece | |
WG 2 | Latvia | |
WG 2 | Portugal | |
WG 2 | Serbia | |
WG 2 | Switzerland | |
WG 2 | Switzerland | |
WG 2 | Austria | |
WG 2 | Italy | |
WG 2 | Portugal | |
WG 2 | Serbia | |
WG 2, WG 3 | Spain | |
WG 2, WG 3 | Switzerland | |
WG 2, WG 3 | Italy | |
WG 2, WG 3, WG 4 | France | |
WG 2 | Israel | |
WG 2 | Spain | |
WG 3, WG 4, WG 5 | Albania | |
WG 3, WG 4, WG 5 | ||
WG 3 | France | |
WG 3 | ||
WG 3 | Lithuania | |
WG 3, WG 4 | Norway | |
WG 3 | Spain | |
WG 3 | ||
WG 3 | ||
WG 3 | ||
WG 3 | Austria | |
WG 3, WG 4 | Slovenia | |
WG 3 | Spain | |
WG 4 | ||
WG 4 | Belgium | |
WG 4 | Bosnia & Herzegovina | |
WG 4 | Germany | |
WG 4 | Luxembourg | |
WG 4 | ||
WG 5 | Croatia | |
WG 5 | Estonia | |
WG 5 | Finland | |
WG 5 | Italy | |
WG 5 | Malta | |
WG 5 | Malta | |
WG 5 | Portugal | |
WG 5 | Italy | |
WG 5 |